Navigation Links
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Date:4/8/2011

among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Virtual Radiologic (vRad), a technology-enabled national radiology practice, ... solution, has been selected by Abbeville Area Medical ... South Carolina. AAMC selected vRad,s ... on-premise PACS that was developed by radiologists for ...
... NEW YORK, Nov. 29, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0693503/Medical-Devices---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics This ... from the following Asian countries: Azerbaijan, China, ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Medical Devices - Asia 2
(Date:7/13/2014)... According to the Living With KP book ... guide that features a series of tips and advice ... pilaris). This guide consists of 14 chapters including:, ...     Chapter 2: What Cause KP? ,     Chapter ... ,     Chapter 4: Keratosis Pilaris Treatment , ...
(Date:7/12/2014)... The Chicken Egg Production ... years, buoyed by stable demand for industry products as ... are a relatively affordable staple for most families across ... grows in line with the size of the population,” ... for new specialty egg products with enriched qualities, such ...
(Date:7/12/2014)... HealthDay Reporter SATURDAY, July 12, 2014 (HealthDay ... technique used to grind up uterine growths and remove them ... to other parts of a woman,s body, U.S. health advisers ... Drug Administration also said that women who do undergo the ... written consent stating that they understand the potential risks, the ...
(Date:7/12/2014)... fastest-growing mobile technology is LTE (Long Term Evolution). The ... to grow due to the rapid evolution of LTE. ... traffic, which is a major driver for the Communications ... equipment comply with industry standards, and services which meet ... is estimated to grown from $3.75 billion in 2013 ...
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 "The ... so it’s uncomfortable and painful to wear shoes," said an ... a special sock that prevents this from happening. , He ... an effective way to prevent the second and big toes ... more endurance while wearing shoes. Ergonomic and easy to use, ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5
... ... Conference Scholarship Writing Contest , ... Green Bay, WI (Vocus) - Undergraduate nursing students have an opportunity of a lifetime: ... an international nursing conference in Madrid, Spain. , , , , ,The article writing ...
... , , Alarming comments by ... , , WASHINGTON, Sept. 17 Later today, ... AIDS Coordinator. "While we welcome Ambassador Goosby to his new ... range of issues that affect the health and well-being of the ...
... , , , ... Centre and ActionAid International USA both receive funding to help ... , , NORTH WEST FRONTIER PROVINCE, ... granted over US$65,000 to provide food, medication, cattle and livestock ...
... BETHPAGE, N.Y., Sept. 17 The Lustgarten Foundation, the ... treatment of pancreatic cancer, today issued the following statement on ... Brand. , , Kerri Kaplan, Lustgarten ... sincere condolences to Mr. Brand,s family and the entire NCAA ...
... , BATESVILLE, Ind., Sept. 17 The Board ... plans to facilitate the orderly succession and retirement of Peter H. Soderberg, president ... arrival in 2006 and endorsed by the Board at that time, Soderberg will ... 2011 (at age 65). , , The Board ...
... SEATTLE, Sept. 17 National science and engineering company Integral ... Mr. Sean Kosinski to its geochemistry and hydrogeology team. With ... increasing demand for specialized technical expertise to support mine permitting, ... "Integral is pleased to have such excellent people join our ...
Cached Medicine News:Health News:Write your Ticket to Madrid, Spain! 2Health News:Write your Ticket to Madrid, Spain! 3Health News:Are Obama Administration Policies Undermining Global AIDS and Health Responses? 2Health News:Are Obama Administration Policies Undermining Global AIDS and Health Responses? 3Health News:The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 2Health News:Hill-Rom Announces CEO Succession Plan 2Health News:Hill-Rom Announces CEO Succession Plan 3Health News:Hill-Rom Announces CEO Succession Plan 4Health News:New Hires Signal Continued Expansion of Integral Consulting's Geochemistry, Hydrogeology, and Mining Capabilities 2
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
Medicine Products: